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J.R.T.C. Roelandt3 and D. Poldermans3*Departments of 1Cardiology, 2Anesthesiology and 3Vascular Surgery, Erasmus MC, Rotterdam,
the NetherlandsObjective. To investigate the combined beneficial effect of statin and beta-blocker use on perioperative mortality and
myocardial infarction (MI) in patients undergoing abdominal aortic aneurysm surgery (AAA).
Background. Patients undergoing elective AAA-surgery identified by clinical risk factors and dobutamine stress
echocardiography (DSE) as being at high-risk often have considerable cardiac complication rate despite the use of beta-
blockers.
Methods. We studied 570 patients (mean age 69G9 years, 486 males) who underwent AAA-surgery between 1991 and
2001 at the Erasmus MC. Patients were evaluated for clinical risk factors (ageO70 years, histories of MI, angina, diabetes
mellitus, stroke, renal failure, heart failure and pulmonary disease), DSE, statin and beta-blocker use. The main outcome was
a composite of perioperative mortality and MI within 30 days of surgery.
Results. Perioperative mortality or MI occurred in 51 (8.9%) patients. The incidence of the composite endpoint was
significantly lower in statin users compared to nonusers (3.7% vs. 11.0%; crude odds ratio (OR): 0.31, 95% confidence
interval (CI): 0.13–0.74; pZ0.01). After correcting for other covariates, the association between statin use and reduced
incidence of the composite endpoint remained unchanged (OR: 0.24, 95% CI: 0.10–0.70; pZ0.01). Beta-blocker use was also
associated with a significant reduction in the composite endpoint (OR: 0.24, 95% CI: 0.11–0.54). Patients using a
combination of statins and beta-blockers appeared to be at lower risk for the composite endpoint across multiple cardiac risk
strata; particularly patients with 3 or more risk factors experienced significantly lower perioperative events.
Conclusions. A combination of statin and beta-blocker use in patients with AAA-surgery is associated with a reduced
incidence of perioperative mortality and nonfatal MI particularly in patients at the highest risk.Keywords: Statins; Beta-blockers; Aortic aneurysm surgery.Introduction
Despite recent advances in perioperative care the 30-
day mortality of elective abdominal aortic aneurysm
(AAA) surgery still varies between 2.7 and 5.5% in
selected series, up to 9% in population based studies.1,
2 In fact, cardiac related morbidity and mortality are
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going AAA-surgery have severe coronary artery
disease (CAD), whereas only 6% have normal coron-
ary arteries.5,6 Clinical risk assessment tools7–9 have
been used to risk stratify patients, and thereby
identifying those at particular benefit from beta-
blockers.10,11 In two separate studies perioperative
beta-blocker use was shown to be associated with a
significant reduction in cardiac death and nonfatal
myocardial infarction.10,11 However, all patients are
not equally protected by beta-blocker therapy.12
Patients identified by clinical risk factors and dobuta-
mine stress echocardiography (DSE) as being at high-
risk often have a considerable cardiac complicationEur J Vasc Endovasc Surg 28, 343–352 (2004)
doi:10.1016/j.ejvs.2004.07.008, available online at http://www.sciencedirect.com onved.
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additional treatment options are necessary to improve
perioperative prognosis in high-risk patients under-
going major vascular surgery. In that respect, we have
previously shown that patients who underwent major
vascular surgery and were statin users had a reduced
risk of perioperative mortality as compared to nonu-
sers.13 However, in this case–control study, we did not
adjust for important predictors of perioperative
mortality such as chronic pulmonary disease,14 DSE
results, and a mix of acute and elective vascular
surgery patients were studied. Recently, Kertai et al.
showed that patients who survived AAA-surgery and
were statin users had a significantly lower incidence of
long-term all-cause and cardiovascular mortality
compared with nonstatin users.15 The current study
builds on the same group of patients examining their
perioperative course in relation to clinical risk factors,
DSE results, a combination of statin and beta-blocker
use and the incidence of perioperative mortality and
nonfatal myocardial infarction.MethodsPatients and study design
The Erasmus Medical Center (MC) is an academic
hospital in Rotterdam, the Netherlands, which acts as
a tertiary referral center for approximately 30 affiliated
hospitals. Between January 1991 and December 2001, a
total of 75,581 patients over 18 years of age underwent
108,613 noncardiac surgical procedures at the Erasmus
MC. Each surgical technique performed was classified
by treating physicians according to a standardized
national coding system that was developed in co-
operation with the National Health Service and
medical insurance companies. The type of surgery,
demographic data, medical history, and information
on the perioperative course of each patient was then
systematically uploaded to an electronic database
maintained by the Medical Information Department;
via this database 570 patients were identified who
underwent elective open infrarenal abdominal aortic
surgery.Data collection and definition of risk factors
Along with clinical information, we also reviewed
medical files and discharge letters for additional
information on clinical risk factors, chronic cardiac
medication use, intraoperative and perioperative
hospital course, and cause and type of perioperativeEur J Vasc Endovasc Surg Vol 28, October 2004complications. Potential clinical determinants of peri-
operative mortality and MI were advanced age (O70
years), gender, current stable or prior angina pectoris,
prior MI on the basis of medical history or a finding of
pathologic Q waves on the electrocardiography,
compensated congestive heart failure or a history of
heart failure, renal dysfunction (serum creatinine O
2 mg/dl (180 mmol/l)), current oral or insulin treat-
ment for diabetes mellitus, a history of prior cerebro-
vascular accident including transient ischemic attack,
hypertension, chronic pulmonary disease (forced
expiratory volume in 1 s !75% of normal adjusted
for age and gender) and smoking.14,16,17 The average
of two fasting levels of total cholesterol, LDL and HDL
cholesterol levels were also included if they were
measured 3 months prior to abdominal aortic surgery.
Patients were defined as having elevated cholesterol
levels if total serum cholesterol level exceeded
212.7 mg/dl (5.5 mmol/l) or the LDL cholesterol
level was higher than 135.3 mg/dl (3.5 mmol/l). In
addition, data from the preoperative DSE were also
collected if available. DSE was performed as pre-
viously described,11 and a positive test result for DSE
was considered if new wall-motion abnormalities
occurred. In addition, the year of operation was also
included given the influence of advances in perio-
perative care and surgical techniques.Chronic medication use
According to routine procedure at Erasmus MC,
patients visited the outpatient clinic at least three
months prior to the planned major vascular surgery,
and all patients were also screened for medication use
in conjunction their medical history. During the study
period additional cardiac medications including beta-
blockers or statins were prescribed at the discretion of
the attending physicians. Patients continued taking
their cardiac medication also on the day of surgery,
and oral medication use was resumed on day 1 after
surgery. Based on institutional guidelines aspirin use
was discontinued at least 10 days before elective AAA-
surgery. Two investigators (JK, DP), blinded to the
patients’ perioperative outcome, reviewed medical
records for medication use including aspirin, ACE-
inhibitor, beta-blocker and statin use. Chronic medi-
cation use was ascertained if medication use was
documented at least one to three months prior to
hospital admission for surgery.Definition of perioperative events
As part of the routine postoperative management all
Statins, Beta-blockers and Aortic Aneurysm Surgery 345patients were screened for cardiac enzyme elevations
(creatine-kinase (CK), creatine-kinase MB (CK-MB),
cardiac troponin T), and 12-lead electrocardiogram
was made after major vascular surgery (day 2, 3 and 7
or discharge). Perioperative events were defined as a
composite of all-cause mortality and MI occurring
before discharge or within 30 days after surgery,
whichever came first. The cause of perioperative death
was retrieved from hospital records or autopsy results.
MI was diagnosed according to our institutional
laboratory protocol as a serum CK level of more than
190 U/l, and a CK-MB activity above 24 IU/l, or the
CK-MB activity fraction exceeding 6% of total CK, or
from 1996 as cardiac troponin TO0.1 ng/ml, and by
new Q waves O1 mm or O30 ms.Statistical analysis
Continuous variables were described as mean valueG
SD, and categorical variables as percent frequencies.
Differences between patient subgroups were evalu-
ated by using the t-test or chi-square test, as appro-
priate. The number of perioperative events in the
study was relatively limited. Therefore, to avoid
overfitting and to enable assessment of the relation
between clinical risk factors and the composite of all-
cause mortality and nonfatal MI, we used the revised
cardiac risk index developed by Lee et al.9 Since the
decision to prescribe statin or beta-blocker therapy
was not randomized, adjustments were made for
baseline characteristics that may have influenced the
decision to use either medication. Separate propensity
scores were constructed using multiple logistic
regression analyses. Baseline clinical characteristics
that had an independent association with the decision
to prescribe statins or beta-blockers (PZ0.25) were
included in the multivariable propensity score. Uni-
variable logistic regression analyses were performed
to study the relation between statin, beta-blockers,
baseline clinical characteristics and the composite
endpoint.
Multivariable logistic regression analysis was also
performed to study the association of statins and beta-
blockers with the composite endpoint, with adjust-
ments for baseline clinical characteristics and the two
propensity scores. The discriminatory power of the
multivariable regression model was quantified by
the c-index, which is identical to the area under the
receiver operating characteristic curve; the c-index
ranges from 0.5 (not predictive at all) to 1.0 (optimal
performance). The performance of the multivariate
regression model was further assessed with Hosmer–
Lemeshow goodness-of-fit test.18 Finally, to reveal apossible heterogeneity between statin or beta-blocker
use and baseline clinical characteristics interaction
terms were included in the models. Odds ratios (ORs)
and corresponding 95% confidence intervals (CIs) are
reported. All analyses were performed using SPSS
statistical software (SPSS Inc., Chicago, Illinois, ver-
sion 11.0).ResultsPatient characteristics
Patient characteristics according to statin use are
described in Table 1. Statin users were more often
younger, women, and had a higher body mass index
than nonusers. Furthermore, statin users had a higher
prevalence of cardiovascular disease; a higher preva-
lence of renal dysfunction, more often underwent
prior coronary revascularization, and had a lower
prevalence of chronic pulmonary disease. There were
no significant differences in total cholesterol, LDL- and
HDL-cholesterol levels between statin users compared
to nonusers. Statin users more frequently used con-
comitant cardiac medications compared to statin
nonusers. Of the 570 patients, 340 also underwent
DSE one to three months prior to surgery. Patients who
were statin users more often had a positive DSE
compared to nonusers. In 162 patients who were statin
users the most frequently prescribed statins were
simvastatin (71.6%), atorvastatin (14.8%), pravastatin
(8.6%), cerivastatin (3.7%) and fluvastatin (1.2%),
respectively. Perioperative mortality or MI occurred
in 51 (8.9%) patients. Among these, there were 24
(47%) cardiovascular complications: 18 cardiac deaths,
four nonfatal MIs and stroke in two patients. The most
common non-vascular causes of death were septic
complications in 10, respiratory insufficiency in nine
and intestinal necrosis in eight patients. Autopsy was
performed in 28 (55%) patients. In patients who died
and underwent postmortem examination the cause of
death was more often classified as cardiac death (50%)
than in patients who died but did not undergo autopsy
(21%).Univariable analyses
A history of chronic pulmonary disease was the most
important determinant of the composite endpoint
(Table 2). Patients with a history of chronic pulmonary
disease had an almost 5-fold increased risk of
perioperative adverse events compared to patients
without such history. Other significant univariableEur J Vasc Endovasc Surg Vol 28, October 2004
Table 1. Characteristics of the population
Characteristics Patients who used statins*,
NZ162 (%)
Patients who did not use
statins, NZ408 (%)
P-value†
Demographics
Age, years 65.1G8.9 70.5G8.6 !0.001
AgeO70 years 61 (38) 258 (63) !0.001
Male sex 126 (78) 360 (88) 0.002
Clinical variables
Body mass index (kg/m2) 25.8G3.5 24.7G2.8 0.002
Current smoker 49 (30) 130 (32) 0.7
Blood pressure (mmHg)
Systolic 146.7G20.3 146.2G19.6 0.8
Diastolic 85.2G10.4 86.0G11.0 0.5
Cholesterol (mmol/l (mg/dl))
Total 5.6G1.2 (216G46.4) 5.7G1.1 (220.4G42.5) 0.9
LDL 3.8G1.1 (146.9G42.5) 3.8G0.6 (146.9G23.2) 0.8
HDL 1.1G0.5 (42.5G19.3) 1.1G0.3 (42.5G11.6) 0.8
Medical history
Current or stable angina pectoris 47 (29) 67 (16) 0.001
Previousmyocardial infarction 61 (38) 78 (19) !0.001
Congestive heart failure 8 (5) 11 (3) 0.2
Diabetes mellitus 14 (9) 22 (5) 0.2
Prior cerebrovascular accident 21 (13) 64 (16) 0.4
Renal insufficiency 16 (10) 15 (4) 0.007
Pulmonary disease 27 (17) 124 (30) 0.001
Hypertension 77 (47) 200 (49) 0.8
Prior coronary revascularization‡ 24 (15) 23 (6) 0.001
Chronic cardiac medication
ACE inhibitors 69 (43) 113 (28) 0.001
Aspirin 57 (35) 72 (18) !0.001
Beta-blockers 103 (64) 153 (38) !0.001
Dobutamine stress echocardiography 0.03
New wall motion abnormalities 32 (20) 49 (12)
No new wall motion abnormalities 75 (46) 184 (45)
No test performed 55 (34) 175 (43)
* All data are presented as number (percentage) unless otherwise indicated; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
For definition of risk factors see Methods.
† Chi-square test or independent t-test.
‡ It is a combination of prior coronary bypass graft surgery and percutaneous transluminal coronary angioplasty (only one procedure
performed in each group).
M. D. Kertai et al.346predictors of the composite endpoint were prior
cerebrovascular accident, renal dysfunction, advanced
age (O70 years) and previous MI. A positive DSE
result was also a significant univariable predictor of
perioperative events. Patients with a new wall-motion
abnormality during DSE had a significantly higher
rate of perioperative mortality or nonfatal MI than
patients without stress induced myocardial ischemia
(17.3% vs. 7.3%; P!0.001). Although there was a
positive trend for improved perioperative outcome in
patients who underwent previous coronary revascu-
larization this association was not statistically signifi-
cant (Table 2). There was no significant association
between the year of operation and the composite
endpoint (crude OR, 1.0, 95% CI, 0.9–1.1). In further
univariable analyses, patients using statins or beta-
blockers were at a significantly lower risk of perio-
perative adverse events compared to patients not
using either of these medications. Compared withEur J Vasc Endovasc Surg Vol 28, October 2004nonusers, patients who were using statins had a three-
fold reduced risk- and patients using beta-blockers
had a two-fold lower risk of the composite endpoint.
There was a trend for aspirin and ACE inhibitors to
reduce the incidence of perioperative events, however,
this association was not statistically significant.Propensity to prescribe statins or beta-blockers
The propensity score for statin use showed that
patients were more likely to be prescribed statins if
they were younger, had a history of CAD or renal
dysfunction, or had elevated total cholesterol levels
(Table 3). The propensity score for beta-blocker use
showed that beta-blockers were more often used if
patients were younger, or had a history of CAD, but
were used less often in those with chronic pulmonary
disease (Table 3).
Table 2. Univariable relation between clinical characteristics and perioperative mortality or myocardial infarction (NZ570)
Variables* No. of patients Perioperative mortality or
myocardial infarction, no. (%)
Odds ratio
(95% confidence interval)
X2 test P-value
Demographics
Age, years
O70 319 38 (11.9) 2.5 (1.3–4.7) 7.4 0.007
!70 251 13 (5.2) 1
Gender
Men 486 42 (8.6) 0.78 (0.36–1.68) 0.4 0.5
Women 84 9 (10.7) 1
Medical history
Current or stable angina pectoris
Yes 114 14 (12.3) 1.6 (0.8–3.0) 8.1 0.2
No 456 37 (8.1) 1
Previous myocardial infarction
Yes 139 20 (14.4) 2.2 (1.2–3.9) 6.4 0.01
No 431 31 (7.2) 1
Congestive heart failure
Yes 19 4 (21.1) 2.9 (0.9–9.0) 3.3 0.07
No 551 47 (8.5) 1
Diabetes mellitus
Yes 36 6 (16.7) 2.2 (0.9–5.5) 2.7 0.1
No 534 45 (8.4) 1
Prior cerebrovascular accident
Yes 85 20 (23.5) 4.5 (2.4–8.4) 22.7 !0.001
No 485 31 (6.4) 1
Renal insufficiency
Yes 31 8 (25.8) 4.0 (1.7–9.5) 10.0 0.002
No 539 43 (7.9) 1
Pulmonary disease
Yes 151 30 (19.8) 4.7 (2.6–8.5) 26.1 !0.001
No 419 21 (5.0) 1
Prior coronary revascularization†
Yes 47 3 (6.4) 0.7 (0.2–2.3) 0.4 0.5
No 523 47 (9.0) 1
Dobutamine stress echocardiography
New wall
motion
abnormalities
81 14 (17.3) 2.5 (1.2–5.2) 5.5 0.02
No new wall
motion
abnormalities
259 19 (7.3) 0.9 (0.5–1.8) 0.04 0.8
No dobuta-
mine stress
echocardiogra-
phy
230 18 (7.8) 1
Chronic cardiac medication
Statins
Yes 162 6 (3.7) 0.31 (0.13–0.74) 7.0 0.01
No 408 45 (11.0) 1
Beta-blockers
Yes 256 15 (5.8) 0.48 (0.26–0.90) 5.2 0.02
No 314 36 (11.4) 1
Chronic cardiac medication
Aspirin
Yes 129 9 (6.9) 0.73 (0.34–1.55) 0.7 0.4
No 431 40 (9.2) 1
ACE inhibitors
Yes 182 15 (8.2) 0.88 (0.47–1.67) 0.1 0.7
No 380 35 (9.2) 1
* For definition of risk factors see Methods.
† It is a combination of prior coronary bypass graft surgery and percutaneous transluminal coronary angioplasty (only one procedure
performed in each group).
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risk index
Among the 246 patients with a risk score of one, there
was one perioperative event observed in the 17.5% of
patients using statins and four events (2%) in the
remaining 203 patients (pZ0.8). In the 242 patients
with a risk score of two, 36% were using statins. One
perioperative event (1.1%) occurred in this group,
whereas 24 (15.5%) events were observed in patients
not using statins (p!0.001). Finally, in the 82 patients
with a risk score of 3 or more, 39% were statin users,
and of those 12.5% had perioperative mortality or MI,
while the event rate was 34% in those not using statins
(pZ0.02).Additional beneficial effect of statin use according to
beta-blocker use
Among 103 patients receiving a combination of
beta-blockers and statins only two (1.9%) perio-
perative events occurred compared to 13 (8.5%)
perioperative events in 153 patients using only
beta-blockers (OR, 0.21, 95% CI, 0.05–0.96). In the
314 patients who were beta-blocker nonusers,
18.7% were using statins. Four (6.8%) perioperative
events occurred in this group, whereas approxi-
mately 50% more events occurred in patients whoTable 3. Odds ratios for propensity scores associated with prescripti
Characteristics* Statin use
Regression coef-
ficient
Odds ratio (95%
CI)
P-value
Age K0.07 0.93 (0.91–0.96) !0.001
Male sex K0.79 0.45 (0.26–0.78) 0.005
Current stable or
history of angina
pectoris
0.91 2.50 (1.52–4.10) !0.001
Previous myo-
cardial infarction
1.14 3.12 (1.96–4.96) !0.001
Congestive heart
failure
0.08 1.08 (0.35–3.38) 0.88
Diabetes melli-
tus
0.62 1.86 (0.86–3.90) 0.11
Prior cerebro-
vascular acci-
dent
. . .
Renal dysfunc-
tion
1.03 2.80 (1.25–6.24) 0.01
Chronic pul-
monary disease
K0.78 0.46 (0.27–0.78) 0.004
Elevated total
cholesterol
1.14 3.12 (2.04–4.78) !0.001
* Characteristics that had an independent relationship with the decisi
multivariable logistic regression model to form the propensity score; C
pZ025 level to be included in the multivariable logistic regression mo
Eur J Vasc Endovasc Surg Vol 28, October 2004were nonusers (OR, 0.51, 95% CI, 0.17–1.50). Test
for heterogeneity revealed no evidence for a
differential effect of statin use in these patient
categories (P-value for interactionZ0.36).Multivariable analyses
Patients with advanced age (O70 years) and with a
history of pulmonary disease remained at an
elevated risk for perioperative mortality and non-
fatal MI after an adjustment for the revised cardiac
risk index (Table 4). One point increase in the
revised cardiac risk index was also significantly
associated with adverse perioperative outcomes.
Finally, the association between statins, beta-block-
ers and the composite endpoint remained statisti-
cally significant. Both, statin and beta-blocker use
were associated with 4-fold reduction in periopera-
tive mortality and nonfatal myocardial infarction.
In a separate model, a trend for aspirin and ACE-
inhibitors to reduce the likelihood for perioperative
mortality and MI was revealed but these associ-
ations were not statistically significant. The combi-
nation of the revised cardiac risk index, statin and
beta-blocker use with the corresponding propensity
scores had excellent discriminatory power and
good fit (c-index, 0.86; overall goodness-of-fit
Hosmer–Lemeshow test; X2Z2.9, pZ0.93).on of statin or b-blocker use
b-Blocker use
Regression coef-
ficient
Odds ratio (95%
CI)
P-value
K0.07 0.98 (0.96–1.01) 0.1
K0.40 0.67 (0.41–1.11) 0.12
0.99 2.70 (1.73–4.22) !0.001
1.16 3.18 (2.09–4.83) !0.001
0.23 1.25 (0.46–3.46) 0.66
. . .
0.52 1.68 (1.03–2.76) 0.04
0.54 1.73 (0.80–3.77) 0.17
K0.49 0.61 (0.41–0.96) 0.02
. . .
on to prescribe statins or b-blockers at pZ0.25, and were included the
I, confidence interval. Ellipses indicate variables that did not reach a
dels.
Table 4. Multivariable relation between clinical characteristics, statin and beta-blocker use and perioperative mortality or myocardial
infarction
Variables Odds ratios (95% confidence interval) X2 test P-value
AgeO70 years 3.0 (1.23–7.30) 5.8 0.02
Chronic pulmonary disease 5.57 (2.60–12.0) 19.3 !0.001
Revised cardiac risk index* one point increase 3.52 (2.10–6.03) 21.1 !0.001
Beta-blocker use 0.24 (0.11–0.54) 11.7 0.001
Propensity score for beta-blocker use 3.51 (0.13–92.78) 0.6 0.5
Statin use 0.24 (0.10–0.70) 6.8 0.01
Propensity score for statin use 5.17 (0.34–79.10) 1.4 0.2
* To compose the revised cardiac risk index 1 point is assigned to each of the following characteristics: high-risk type of surgery, known
ischemic heart disease (history of myocardial infarction, positive dobutamine stress echocardiography, history of angina pectoris), history of
heart failure, history of cerebrovascular disease, diabetes mellitus, and preoperative serum creatinine levelO2.0 mg/dl.
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revised cardiac risk index
Based on the number of clinical risk scores, a
combination of statin and beta-blocker use the
incidence of the composite endpoint was calculated
(Fig. 1). Patients with a risk score of 1 had a low
event rate, with those receiving combined therapy
tending to experience the lowest event rates (pZ
ns). Although not statistically significant, a similar
relationship was observed in patients with a risk
score of 2. However, in patients at highest risk (risk 
 
 
Fig. 1. Incidence of perioperative mortality and myocardial infa
by the revised cardiac risk index (ischemic heart disease, his
disease, insulin therapy for diabetes, preoperative serum creatscore of 3 or more) a significant descending
gradation of risk was revealed with those on
combined therapy experiencing only 7.7% perio-
perative event rates.Discussion
The current study showed that clinical risk factors and
DSE data aggregated in the revised cardiac risk index
were significant predictors of perioperative mortality
and nonfatal MI. In addition patients who were statinrction. Results are based on the number of clinical risk factors
tory of congestive heart failure, history of cerebrovascular
inine O2 mg/dl), statin and beta-blocker use.
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M. D. Kertai et al.350users had a four-fold reduced risk of perioperative
events. Although, statin users had a different clinical
risk profile than nonusers, this association remained
after adjustment for these differences. Furthermore,
our findings also suggest the benefit of combined
therapy with statins and beta-blockers especially in
patients at the highest risk as defined by the revised
cardiac risk index.
Clinical predictors of adverse perioperative out-
come for patients with abdominal aortic surgery have
been well documented and clearly identify a history of
CAD, renal dysfunction and pulmonary comorbidity
as having prognostic significance in these patients.14,16,17
Among patients in whom postmortem examination
was performed in the present study, the cause of death
was more often classified as cardiac than in patients
who died but did not undergo autopsy (50% vs. 21%).
This suggests that the incidence and impact of cardiac
complications after abdominal aortic surgery could be
underestimated in clinical practice. There is growing
evidence, which points to an association between the
presence of an AAA, and atherosclerosis,19,20 which
may well explain the observed high proportion of
adverse events due to cardiovascular causes. While
favorable actions of statins on atherosclerosis and
vascular properties have mainly been attributed to
cholesterol lowering,21–27 statins may also attenuate
coronary artery plaque inflammation, influence pla-
que stability in addition to antithrombogenic, anti-
proliferative and leukocyte-adhesion inhibiting
effects.21–23,28 All these properties of statins may
stabilize unstable coronary plaques, and thereby
reducing myocardial ischemia and subsequent myo-
cardial damage.
Consistent with previous studies, an association
between beta-blocker use and reduced perioperative
events was observed.10,11 Statin use appears to be
independently associated with a reduced incidence of
perioperative mortality and MI even in the presence of
beta-blockers. Beta-blockers apart form their direct
hemodynamic effect such as reduction in heart rate
and contractility may also indirectly influence the
determinants of shear stress and reduce inflammation
through decreases in sympathetic tone.29 These prop-
erties of beta-blockers may reinforce the effect of
statins on vulnerable plaques.
To date, there are few studies that have evaluated
the effect of statin use on the reduction of perioperative
and long-term cardiovascular complications in
patients undergoing vascular surgery.15,30–32 The
findings of Lindenauer et al.30 showed in a large
group of patients that treatment with statins was
associated with a significant reduction of in-hospital
mortality across different risk and surgical categoriesEur J Vasc Endovasc Surg Vol 28, October 2004in patient undergoing major noncardiac surgery. In a
clinical trial of Durazzo et al., a marked reduction of
adverse cardiovascular events among vascular surgery
patients who were randomly assigned to atorvastatin
compared with placebo was reported.31 The study
showed that short-term (within 6 months) treatment
with atorvastatin significantly reduced the incidence
of cardiovascular events after vascular surgery (ator-
vastatin vs. placebo, 8.3% vs. 26.0%). Landesberg et
al.32 also found that patients who underwent major
vascular surgery and were using lipid-lowering
therapy had a tendency for better event-free survival
rates. Kertai et al. showed that statin therapy was
associated with a lower all-cause and cardiovascular
mortality during follow-up after AAA surgery.15
In our previous case–control study, we found that
statin users had a four-fold reduction of in-hospital
mortality as compared to nonusers.13 The current
study builds upon these earlier findings by high-
lighting the combined beneficial effect of statin and
beta-blocker use for the reduction of perioperative
mortality and nonfatal MI in a large cohort of patients
undergoing elective AAA-surgery. Secondly, the
revised cardiac risk index was also applied to adjust
for important clinical risk factors and DSE test results.
Finally, we used propensity scores and multivariable
modeling to adjust for potential confounders. Beta-
blockers may offer protection in patients at low- to
intermediate risk but their effect appears to be
marginal in patients at the highest risk.12 In this
context, statins appear to have additional beneficial
effect for the prevention of perioperative mortality and
nonfatal MI.
This study has certain limitations, which should be
considered when interpreting the results. Statin users
had a higher incidence of CAD and renal dysfunction,
and as a result of that, were more often prescribed
other cardiac medications or underwent previous
coronary revascularization prior to the elective AAA-
surgery. It is possible, therefore, that statin users
would have also been more likely to receive better
medical attention during the perioperative period.
Moreover, the incidence of perioperative mortality
was relatively higher than reported from other studies
(2.7–5.5%).14 This may question the generalizability of
our findings. However, it is important to note that
patients in this study were operated in a tertiary
referral center, and studies that reported lower
mortality rates usually implied strict inclusion criteria
and selected patients at low risk for perioperative
complications.14 Finally, given the retrospective nature
of our study it was not possible to ascertain unless it
was clearly stated in the medical records whether
treatment with statins was discontinued throughout
Statins, Beta-blockers and Aortic Aneurysm Surgery 351the perioperative period or discontinued during
hospitalization. This could be particularly relevant
since current American Heart Association Clinical
Advisory Statement on statin safety suggests the
discontinuation of statin treatment during major
surgery or critical illness.33 Conversely a recent study
has suggested that discontinuation of statins may be
associated with adverse outcomes in hospitalized
patients.34Conclusions
This study revealed that a combination of statin and
beta-blocker use in patients undergoing AAA-surgery
is associated with a reduced incidence of perioperative
mortality and nonfatal MI, particularly in patients at
the highest risk for perioperative complications. This
early evidence of the beneficial effect of statin use
particularly in combination with beta-blocker use
should be confirmed in future large-scale clinical
trials.References
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